Section Arrow
AAPG.NASDAQ
- Ascentage Pharma Group
Quotes are at least 15-min delayed:2026/11/08 19:11 EST
Regular Hours
Last
 15.43
+0.3 (+1.98%)
Day High 
15.5 
Prev. Close
15.13 
1-M High
16.5499 
Volume 
5.54K 
Bid
15.09
Ask
15.5
Day Low
15.05 
Open
15.13 
1-M Low
13.46 
Market Cap 
1.41B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 14.73 
20-SMA 14.99 
50-SMA 15.66 
52-W High 34.5 
52-W Low 13.46 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-15.80/12.16
Enterprise Value
2.17B
Balance Sheet
Book Value Per Share
0.89
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
574.12M
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
KPTIKaryopharm Therapeutics Inc.0.0549-0.0052-8.65%-- 
INOInovio Pharmaceuticals1.215-0.235-16.21%-- 
LABTLakewood-Amedex Biotherapeutics Inc0.3863-0.1543-28.54%-- 
CDTCdt Equity Inc1.31+0.464+54.85%0PE
MRNAModerna254.19+12.73+5.27%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies and currently has seven drug candidates in pipeline under research. The company's geographical segments include the United States and Mainland China.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.